Mutual Fund Insights: Jennison Health Sciences C Fund (PHLCX)

In-depth Analysis of Jennison Health Sciences C Fund (PHLCX)

3 months 6 months 1 year 3 year 5 year

See Jennison Health Sciences C Fund (PHLCX) performance details as of January 31, 2010

  

Last Trade: $19.67 on 3/19/2010, Change: 0.00 (0%)

  

Fund Manager - David Chan

Fund Manager Tenure: 10.7 years   [Similar Funds: PHLAX  PHLBX ]
Fundmojo Fund Grade: A (Score: 0.75)     (What does this score mean?)

David Chan is managing director of AGF Asset Management Asia Ltd. Prior to joining forces with AGF to build their Asian division in 1996; David managed Asian equity portfolios for Nomura Capital since 1986.  Get more insights on David Chan

  

 What we like about Jennison Health Sciences C Fund (PHLCX)

Data for Jennison Health Sciences C Fund (PHLCX) as of January 31, 2010

• Jennison Health Sciences C Fund (PHLCX) management has been with Jennison Health Sciences C Fund for 10.7 years
• Jennison Health Sciences C Fund (PHLCX) has good short-term performance (1-year return 25.17% vs 24.07% Health category average)
• Jennison Health Sciences C Fund (PHLCX) has good mid-term performance (3-year return 0.88% vs -0.24% Health category average)
• Jennison Health Sciences C Fund (PHLCX) has good Long-term performance (5-year return 7.38% vs 4.22% Health category average)
• Jennison Health Sciences C Fund (PHLCX) ratio of up-years vs down years is greater than 2
• Jennison Health Sciences C Fund (PHLCX) has a Morningstar rating of 4 and above

  

 What we are cautious about Jennison Health Sciences C Fund (PHLCX)

Data for Jennison Health Sciences C Fund (PHLCX) as of January 31, 2010

• Jennison Health Sciences C Fund is a focused fund with 42.03% of the portfolio on top 10 securities. This tends to produce more volatility compared to a diversified fund. See fund top 10 holdings.
• Jennison Health Sciences C Fund (PHLCX) is more volatile than its peers as it has a 3-year Standard Deviation of 20.98 that is higher than category average of 18.84
• Jennison Health Sciences C Fund (PHLCX) has a higher management fee of 2.00% than its Health average of 1.91%
• Jennison Health Sciences C Fund (PHLCX) carries a 1% load

See Jennison Health Sciences C Fund (PHLCX) performance details as of January 31, 2010

  

  

Interested in other top mutual funds in similar Health category?

Below are some additional Health mutual funds generated out of our database

• Fidelity Select Pharmaceuticals (FPHAX)    [ Compare with Jennison Health Sciences C Fund (PHLCX) ]
• BlackRock Health Sciences Ops Inv A (SHSAX)    [ Compare with Jennison Health Sciences C Fund (PHLCX) ]
• T. Rowe Price Health Sciences (PRHSX)    [ Compare with Jennison Health Sciences C Fund (PHLCX) ]
• See top fund managers for Health Category Funds
• Browse other funds in Health Category

  

Jennison Health Sciences C Fund (PHLCX) Net Asset

Track net asset change of Jennison Health Sciences C fund (PHLCX)

Date	Net Asset
01/2010	$86.21M
11/2009	$78.74M
10/2009	$71.15M

More historic net asset information on Jennison Health Sciences C Fund (PHLCX)

  

Jennison Health Sciences C Fund (PHLCX) Portfolio Allocation

Track portfolio allocation change of Jennison Health Sciences C fund (PHLCX)

Date	Cash	Stock	Bond	Other
09/2009	3.28%	90.07%	0%	6.65%
08/2009	2.39%	89.55%	0%	8.06%
07/2009	2.62%	89.88%	0%	7.5%

Click here to see more historic asset allocation information on Jennison Health Sciences C Fund (PHLCX)

  

Most Recent Top 10 Holdings in Jennison Health Sciences C Fund (PHLCX)

Discover what Jennison Health Sciences C Fund (PHLCX) manager is buying

30-Sep-09 Ironwood Pharm Series E [5.08%] AMAG Pharmaceuticals, Inc. [4.8%] Celgene Corporation [4.29%] Vertex Pharmaceuticals Incorpor [4.25%] Alexion Pharmaceuticals, Inc. [3.84%] Shire plc [3.78%] BioMarin Pharmaceutical Inc. [3.45%] Allos Therapeutics, Inc. [3.32%] Mylan Inc. [3.14%] Incyte Corporation [2.91%]

31-Aug-09 Ironwood Pharm Series E [5.23%] AMAG Pharmaceuticals, Inc. [4.75%] Vertex Pharmaceuticals Incorpor [4.42%] Alexion Pharmaceuticals, Inc. [4.1%] Shire plc [3.77%] Allos Therapeutics, Inc. [3.55%] Celgene Corporation [3.41%] BioMarin Pharmaceutical Inc. [3.31%] Mylan Inc. [3.04%] Incyte Corporation [2.99%]

31-Jul-09 AMAG Pharmaceuticals, Inc. [5.32%] Ironwood Pharm Series E [5.31%] Vertex Pharmaceuticals Incorpor [4.31%] Alexion Pharmaceuticals, Inc. [4.05%] Allos Therapeutics, Inc. [3.95%] Celgene Corporation [3.77%] Gilead Sciences, Inc. [3.53%] United Therapeutics Corporation [3.48%] Shire plc [3.45%] BioMarin Pharmaceutical Inc. [3.34%]

Click here for Stock Holding Change Map in Jennison Health Sciences C Fund (PHLCX)

  

Related books and products to Jennison Health Sciences C Fund (PHLCX)

  

Latest News on Jennison Health Sciences C (PHLCX)

See what is happening with Jennison Health Sciences C Fund (PHLCX)

Yahoo! Finance: RSS feed not found See more news on Jennison Health Sciences C Fund (PHLCX)

 

Books and Resources

 

 

See more information on Jennison Health Sciences C Fund (PHLCX)

• Jennison Health Sciences C Fund Insights
• Jennison Health Sciences C Fund Performance Data
• Jennison Health Sciences C Fund News
• Jennison Health Sciences C Fund Score Explaination
• Jennison Health Sciences C Fund Manager Information
• Historic Jennison Health Sciences C Fund Asset Allocation Report
• Historic Jennison Health Sciences C Fund Top 10 Holding Tracking
• Historic Jennison Health Sciences C Fund Asset Under Management Tracking